Member Info for Laura2022

Zofty

Hope you dont spend 3yrs on here like on HE1

16yrs on LSE to waste your time on shares you don't own

You live your best life :)

Exactly

So not just me that sees through this new ID

Overhang gone

Of delayed buys

Nice buying

As i said 2 weeks ago

A total nuisance new ID

Talks nonsense ACROSS LSE

One either believes this legally binding RNSs information and believe under 5p is a bargain

OR

You don't/never will and move on rather than constantly moan on LSE with old or newly invented IDs

The structure of the Lanstead subscription provides a mechanism through which the Company may potentially benefit from future share price performance, with the 8p Benchmark Price acting as the reference point for returns under the Sharing Arrangement. The Board therefore believes that continued operational progress and news flow relating

P140 and Kapiglucagon, have the potential to support value creation over the period of the agreement.

Importantly, the successful fundraising extends the Company's cash runway to at least H2 2028*. This strong financial leverage enhances our ability to negotiate a P140 licensing agreement from a position of strength, while also providing the flexibility to accelerate the Kapiglucagon program and selectively invest in earlier-stage pipeline opportunities.

 

With the progress already underway, the Board believes 2026 will be a year of delivery, momentum, and success for ImmuPharma and its shareholders.

Some people on here are incredible

After 2yrs...just sell up..but they either

1) have but still whinge

2) haven't but wont sell

Its why 10-15 been filtered last 6weeks

Buys are 42.2p to 42.4p

Seller nearly out who caused this slump

GEX helium money will come here

I've added more today here

Funding of c £16mln with over £5mln raised

Assets value $300mln ( this was based on 2025 pricing)

USA based helium assets

Helium spot prices up 50% in February, and further still in March, April Bupa warns of shortages as does Elon Musk

April Placing and comments

Cornerstoned by institutional investors following inbound demand

· Validates the strength of Quantum's helium portfolio and US strategic positioning

· Funding supports the next phase of development at Sagebrush and Coyote Wash

· Multiple near-term catalysts, including results from the Company's extended production test at Sagebrush

Shows the value of helium deals

QHE fully funded next..any day for drill RNS

IES shows what happens when a very large orders comes in a much needed sector

1) shirts will need to close soon

2) undervalued

3) charts battered from £5.00

4)Persimmon etc may be looking at acquisitions as M and A across FTSE 100-350 continues last 15mths

Premium takeovers of at least 50-60%% last 6mths alone

Excellent progress

The AGM will be held at 9:00am (BST) on 24 June 2026 at Microlise's head office at Farrington Way, Eastwood, Nottingham, NG16 3AG.

 

Dividend Timetable

As announced in the results for the year ended 31 December 2025 on 14 May 2026, the Board are recommending the payment of a final dividend for FY25 of 1.30 pence per ordinary share. Subject to shareholder approval at the Annual General Meeting, the dividend will be paid on 24 July 2026 to shareholders on the register at the close of business on 3 July 2026.

 

Https://www.defenceonline.co.uk/2026/05/20/18-billion-defence-spending-boost-expected-to-unlock-full-strategic-defence-review-programme/

The Ministry of Defence is set to receive an £18 billion boost to its budget over the next four years, in an investment expected to be approved by Prime Minister Sir Keir Starmer this week and described by defence sources as “great news.”

The increase, if confirmed, would allow the MoD to fulfil all 62 recommendations contained in the Strategic Defence Review, giving the armed forces the financial foundation needed to modernise, re-equip and prepare for the demands of future warfare.

What the Investment Would Unlock

The Strategic Defence Review set out an ambitious programme of capability investment spanning autonomous systems, nuclear deterrence, land forces modernisation, digital transformation, naval shipbuilding and supply chain development. Many of those recommendations have been constrained by the gap between ambition and available funding. An £18 billion settlement spread over four years would, according to reports, provide sufficient headroom to move all 62 recommendations from aspiration to funded programme.

For the defence supply chain, the implications are substantial. Programmes that have been in planning, demonstration or early development phases would be expected to progress to contract. Capability gaps identified in the review, from artillery replenishment to autonomous systems and infrastructure modernisation, would receive the sustained investment needed to generate real procurement activity.

Also

Will massively help RCFX

The balance sheet is a fortress for a £49mlm market cap company. £16.7m cash, zero debt drawn, £30m facility sitting there untouched. Cash conversion at 142% of adjusted EBITDA is exceptional — that £6.2m working capital inflow (driven by a £5.2m reduction in trade debtors) shows the subscription billing model working exactly as it should. They're not burning cash to grow; the operating model genuinely throws off cash.

The market position is structurally defensible. Canaccord's stat that Microlise has c.58% share of UK HGV fleets with 500+ vehicles is remarkable

Thanks Trench

Interesting times given Richard Edwards background in A.i

Strong cash generation with adjusted operating cash flow5 of £13.3m (FY24: £10.3m), and a robust balance sheet with £16.7m of cash (FY24: £11.4m) and a £30m undrawn debt facility, consisting of a £10m committed revolving cash flow facility and a £20m accordion with HSBC.

· Dividends of £2.1m paid (FY24: £2.7m), with a proposed final dividend of 1.30p (FY24: 1.24p), in line with the Board's progressive dividend policy.(currently 4.5% at current prices )